中国人寿(601628):盈利超预期高增,NBV增幅进一步走阔:——中国人寿(601628.SH、2628.HK)2025年三季报点评
EBSCN·2025-10-31 03:08

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company [1][6]. Core Views - The company reported a significant increase in profit, with a net profit of 167.8 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 60.5% [4]. - The new business value (NBV) showed a robust year-on-year increase of 41.8%, indicating strong growth potential [5]. - The company is focusing on value creation and transformation, with ongoing marketing system reforms and a shift towards floating income-type products [6]. Financial Performance - For the first three quarters of 2025, the company achieved an operating income of 537.9 billion yuan, up 25.9% year-on-year [4]. - The return on equity (ROE) reached 29.3%, an increase of 9.3% compared to the previous year [4]. - The annualized total investment return rate improved by 1.0 percentage point to 6.4% [5]. Business Development - The company’s premium income for the first three quarters was 669.65 billion yuan, reflecting a 10.1% increase year-on-year [5]. - The new single premium income was 218.03 billion yuan, with a year-on-year growth of 10.4% [5]. - The company’s sales force remained robust, with a total of 657,000 sales personnel, maintaining its leading position in the industry [4]. Profit Forecast and Valuation - The profit forecast for the company has been revised upwards, with expected net profits of 173.8 billion yuan, 189.4 billion yuan, and 206.7 billion yuan for 2025, 2026, and 2027 respectively [6][8]. - The current price-to-earnings (P/E) ratio for A-shares is 7.22, while for H-shares it is 3.75, indicating attractive valuation levels [8].